Regeneron Covid-19 therapy cuts deaths among hospitalised patients who lack antibodies: Study

The therapy, Regen-Cov, has been granted emergency use authorisation for people with mild-to-moderate Covid-19 in the United States.
The therapy, Regen-Cov, has been granted emergency use authorisation for people with mild-to-moderate Covid-19 in the United States.PHOTO: REUTERS

LONDON (REUTERS) - Regeneron Pharmaceuticals's Covid-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday (June 16) found.

The therapy, Regen-Cov, has been granted emergency use authorisation for people with mild to moderate Covid-19 in the United States, but results from the Recovery trial provide the clearest evidence of its effectiveness among hospitalised patients.

It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with Covid-19 whose immune system had not mounted an antibody response, known as seronegative.

The result translates into six fewer deaths for every 100 seronegative patients treated with the therapy, researchers said.

There was no discernible effect of the treatment on those who had generated natural antibody responses and were seropositive.

"People have been very, very sceptical that any treatment against this particular virus would work by the time people get to hospital," Mr Martin Landray, the joint chief investigator on the trial, told reporters.

"If you haven't raised antibodies of your own, you really would benefit from getting some," he said.

The treatment also shortened the hospital stay of those who were seronegative and reduced their chances of needing a mechanical ventilator, said Mr Landray.

Regeneron had previously said its treatment had shown enough promise in hospitalised patients to warrant continuing its trial. This data provides the first large-scale confirmation of that assertion.

There were 9,785 patients hospitalised with Covid-19 who were randomly allocated to receive usual care plus the antibody combination therapy or just usual care, of which 30 per cent were seronegative.

The Recovery trial also showed the steroid dexamethasone and Roche's arthritis drug Actemra (tocilizumab) cut deaths in hospitalised patients.

While those treatments focus on inflammation caused by reaction to the coronavirus, Regeneron's therapy, which belongs to a class of biotech drugs called monoclonal antibodies, mimic natural antibodies the body produces to fight off the infection.

"This is the first time we've got one that's actually targeting the virus itself," said Mr Landray, adding that it could be used along with other treatments.

"It's not that you do one thing or another thing. These benefits are additive in these patients," he said.

Other companies have been developing similar treatments.

US emergency use authorisation has been granted to antibody treatments developed by Eli Lilly and Co as well as by Vir Biotechnology with GlaxoSmithKline. Both are approved for use in mild to moderate cases.

On Tuesday, AstraZeneca said its antibody therapy had shown no evidence of protecting people from developing the disease following exposure, although other trials of its cocktail as a prevention or a treatment are ongoing.

Mr Landray said the Recovery results should give developers of other monoclonal antibody therapies optimism that they can also be used in some hospitalised patients.

"This opens up the possibility for many, many others," he said.

"People see a few negative trials and they say 'well that'll never work' and they opt out and go off and do something else.

(But) this is very, very clear, the picture that we've got from this trial."